
The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.
Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the next steps with sipuleucel-T (Provenge) for patients with prostate cancer.
Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the next steps with sipuleucel-T (Provenge) for patients with prostate cancer.
Cellular studies are still needed to investigate the immune response caused by sipuleucel-T, explains Sartor.
Additionally, studies are needed to determine if immunotherapies are more active in different patient populations, states Sartor.






